Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Drug: MDA; Drug: Placebo

• Registration Number: NCT00823407
• Lead Sponsor: California Pacific Medical Center Research Institute

Brief Summary

The purpose of this study is to investigate the pharmacological and cognitive effects of MDA in healthy humans.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Study First Submitted: 2009-01-14
• Study First Submitted QC: 2009-01-14
• Study First Posted: 2009-01-15
• Primary Completion: 2009-07
• Study Completion: 2009-07
• Status Verified: 2013-05
• Last Update Submitted: 2013-05-29
• Last Update Posted: 2013-05-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Healthy males and females age 18-50
• Fluent English speaker
• Willing and able to give written consent

Exclusion Criteria

• Body mass index > 30 or < 18
• Pregnancy or lactation

FOR MORE DETAILS CONTACT THE RESEARCH CLINIC.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
MDA	MDA	-
MDA	Placebo	-

Primary Outcome Measures

Name	Time	Method
MDA will be metabolized to hydroxyamphetamine (HMA) and dihydroxyamphetamine (DHA) and will produce dose-dependent increases in neuroendocrine measures.	0-48 hours post dose

Secondary Outcome Measures

Name	Time	Method
MDA will produce dose-dependent increases in self-report entactogen-like and stimulant like measures.	0-48 hours post dose

Trial Locations

Locations (1)

CPMC Addiction & Pharmacology Research Laboratory (APRL); 🇺🇸 San Francisco, California, United States